Repare Therapeutics (RPTX) is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its…
clinical studies
Gastroparesis We have all felt bloated after a meal. Usually, some classic Pepto Bismol does the trick, however, some aren’t as lucky. Gastroparesis, also referred to as delayed gastric…
Protagonist Therapeutics (PTGX.Q) announced the receipt of verbal communication from the U.S. Food and Drug Administration (FDA) that the Company’s clinical studies for rusfertide have been placed on a…
Lexaria Bioscience (LXX.C) has received test results for two new DehydraTECH 2.0 cannabidiol (CBD) formulations in its second 2021 applied research and development study program, HYPER-A21-2. “One of our…
Cybin (CYBN.NE) announced that the Institutional Review Board (IRB) has granted them approval to begin the study of its sublingual psilocybin formulation, CYB001, in a Phase II clinical trial…
Tetra Bio-Pharma (TBP.T) has shipped Qixleef, its investigational new drug, to the United States for initiation of the REBORN1 study. The REBORN1 study will investigate cannabis as an alternative…
Psyched Wellness (PSYC.C) has signed an additional agreement with its contract research organization partner, KGK Science, to further study the anti inflammatory nature of AME-1. “This is a key…
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million…
Algernon Pharmaceuticals (AGN.C) has established a clinical trial program to treat stroke that uses DMT, or (N-dimethyltryptamine) today, according to a press release. The company decided to take a…
The ongoing COVID-19 drama that’s dragged markets to its knees may almost be over, as finally companies have made some headway and there’s a drug out there that’s been…